Published in , 1900
Peer-reviewed journal articles
Blankart KE, Stargardt T. The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. Health Economics. 2020;29(S1):63–82.
Blankart KE, Lichtenberg FR. Are patients more adherent to newer drugs? Health Care Manag Sci. 2020 Aug 8;23:605–18.
Blankart KE, Arndt F. Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany. International Journal of Environmental Research and Public Health. 2020 Jan;17(11):4113.
Winter V, Thomsen MK, Schreyögg J, Blankart K, Duminy L, Schoenenberger L, et al. Improving Service Provision - The Health Care Services’ Perspective. SMR. 2019;3(4):163–83.
Guhl D, Blankart KE, Stargardt T. Service quality and perceived customer value in community pharmacies. Health Services Management Research. 2019 Feb 1;32(1):36–48.
Fischer KE, Koch T, Kostev K, Stargardt T. The impact of physician-level drug budgets on prescribing behavior. Eur J Health Econ. 2018 Mar 1;19(2):213–22.
Hostenkamp G, Fischer KE, Borch-Johnsen K. Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. Health Policy. 2016;120(12):1404–11.
Guhl D, Stargardt T, Schneider U, Fischer KE. Dispensing behaviour of pharmacies in prescription drug markets. Health Policy. 2016 Feb;120(2):190–7.
Fischer KE, Stargardt T. The diffusion of generics after patent expiry in Germany. Eur J Health Econ. 2016 Nov 1;17(8):1027–40.
Fischer KE, Heisser T, Stargardt T. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia. Health Policy. 2016 Oct;120(10):1115–22.
Fischer KE, Stargardt T. Early Benefit Assessment of Pharmaceuticals in Germany Manufacturers’ Expectations versus the Federal Joint Committee’s Decisions. Med Decis Making. 2014 Nov 1;34(8):1030–47.
Fischer KE, Rogowski WH. Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe. International Journal of Environmental Research and Public Health. 2014 May 19;11(5):5403–30.
Fischer KE, Leidl R. Analysing coverage decision-making: opening Pandora’s box? Eur J Health Econ. 2014;15(9):889–906.
Fischer KE, Stollenwerk B, Rogowski WH. Link between Process and Appraisal in Coverage Decisions An Analysis with Structural Equation Modeling. Med Decis Making. 2013 Nov 1;33(8):1009–25.
Fischer KE, Rogowski WH, Leidl R, Stollenwerk B. Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. Health Policy. 2013 Oct;112(3):187–96.
Fischer KE. Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes. BMC Medical Informatics and Decision Making. 2012 Aug 2;12(1):83.
Fischer KE. A systematic review of coverage decision-making on health technologies—Evidence from the real world. Health Policy. 2012;107(2–3):218–30.
Fischer KE, Leidl R, Rogowski WH. A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention. Health Policy. 2011 Aug;101(3):290–9.
Fischer KE, Grosse SD, Rogowski WH. The role of health technology assessment in coverage decisions on newborn screening. International Journal of Technology Assessment in Health Care. 2011;27(04):313–21.
Book chapters
Blankart K. Heilung um jeden Preis? - Die 20.000€ Pille oder die Herausforderung der Preissetzungsstrategie im Gesundheitswesen. In: Ritz A, Sager F, Lienhard A, editors. Fälle zu Public Management und Verwaltungswissenschaft. (forthcoming)
Blankart K. Der strategische Kampf: Wettbewerbsfähigkeit durch die europäische Waren- und Dienstleistungsfreiheit. In: Ritz A, Sager F, Lienhard A, Blankart CRB, editors. Fälle zu Public Management und Verwaltungswissenschaft. (forthcoming)
Articles in German
Kurte MS, Blankart K. Ambulant-sensitive Krankenhausfälle in Deutschland – Abgrenzung, Prävalenz und Kosten. Gesundh ökon Qual manag. 2019 May 7;24(06):277–91.
Fischer K. Ansätze zur empirischen Analyse von Entscheidungen über die Erstattungsfähigkeit von Gesundheitstechnologien in industrialisierten Ländern. RPG Recht und Politik im Gesundheitswesen. 2013;19(3):67–81.
